SCHEMBL2834041

SCHEMBL2834041

C=C(C)COC(=O)c1ccccc1F

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.55
HTT P42858 1/20 0.55
ADRB2 P07550 5/20 0.49
ADRB1 P08588 5/20 0.49
ADRB3 P13945 5/20 0.49
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
NPC1 O15118 1/20 0.46
GAA P10253 2/20 0.46
TSHR P16473 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
KMT2A Q03164 1/20 0.44
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2992727 0.88 TSHR (0.59) TP53HTTALDH1A1LMNANPC1
SCHEMBL10781015 0.81 L3MBTL1 (0.59) HTTALDH1A1KDM4ELMNANPC1
SCHEMBL11678478 0.81 ALDH1A1 (0.57) TP53ALDH1A1KDM4ELMNANPC1
SCHEMBL2831819 0.81 KMT2A (0.59) HTTALDH1A1KDM4ELMNANPC1
SCHEMBL2829940 0.81 RAB9A (0.57) ALDH1A1NPC1GAACES2CES1
SCHEMBL10905341 0.80 TSHR (0.52) HTTADRB2ADRB1ADRB3ALDH1A1
SCHEMBL4741221 0.79 ALDH1A1 (0.59) TP53HTTADRB2ADRB1ADRB3
SCHEMBL18867935 0.79 TSHR (0.74) TP53HTTADRB2ADRB1ADRB3
SCHEMBL29604433 0.79 TSHR (0.74) TP53HTTADRB2ADRB1ADRB3
SCHEMBL2325118 0.79 TSHR (0.74) TP53HTTADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 TP53 2247/4885HTT 3887/4885ADRB2 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.